 |
138 Diseases |  |
94 Trials |
|
94 Trials |  |
2090 News |  |
| «12...21222324252627282930313233 |
- ||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov) - Apr 15, 2012
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
N=75 --> 60
- |||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-na (clinicaltrials.gov) - Apr 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
N=75 --> 60 Not yet recruiting --> Recruiting
- |||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy (clinicaltrials.gov) - Apr 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Apr 3, 2012
P2, N=450, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Trial withdrawal: Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy (clinicaltrials.gov) - Mar 19, 2012
P4, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Completed --> Withdrawn
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy (clinicaltrials.gov) - Mar 19, 2012
P4, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed --> Withdrawn N=108 --> 0
- |||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Metastases: Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer (clinicaltrials.gov) - Mar 14, 2012
P1/2, N=100, Completed, Sponsor: Mayo Clinic
N=108 --> 0 Active, not recruiting --> Completed
- |||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Metastases: Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (clinicaltrials.gov) - Mar 14, 2012
P2, N=112, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || orteronel (TAK 700) / Takeda
New P3 trial: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P3, N=900, Recruiting, Sponsor: Radiation Therapy Oncology Group
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-na (clinicaltrials.gov) - Mar 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy (clinicaltrials.gov) - Mar 5, 2012
P3, N=164, Recruiting, Sponsor: Takeda
- ||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P2 trial: Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P2, N=52, Completed, Sponsor: Medivation, Inc.
- | leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open: LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) - Feb 28, 2012
P3, N=75, Recruiting, Sponsor: Joseph Mccune
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Capesaris (GTx-758) / Oncternal Therap
Trial termination: Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer (clinicaltrials.gov) - Feb 20, 2012
P2, N=156, Terminated, Sponsor: GTx
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; FDA Clinical Hold
- | leuprolide acetate for depot suspension / Generic mfg., norethindrone / Generic mfg.
Enrollment closed: Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) (clinicaltrials.gov) - Feb 9, 2012
P3, N=112, Active, not recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Terminated; FDA Clinical Hold Recruiting --> Active, not recruiting
- New P2 trial, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Feb 8, 2012
P2, N=2, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy (clinicaltrials.gov) - Feb 1, 2012
P3, N=386, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- MVT-602 / Sumitomo Pharma
Enrollment change: Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=9, Terminated, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=99 --> 9
- | Suprefact (buserelin acetate) / Sanofi
Enrollment open: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Jan 24, 2012
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
N=99 --> 9 Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 17, 2012
P1, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Suprefact (buserelin acetate) / Sanofi
Trial completion, Surgery: Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jan 8, 2012
P3, N=361, Completed, Sponsor: NCIC Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Suprefact (buserelin acetate) / Sanofi
New P3 trial: Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2011
P3, N=192, Recruiting, Sponsor: Proton Collaborative Group
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment change, Metastases: Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=0, Withdrawn, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=132 --> 0
- | docetaxel / Generic mfg.
New P2 trial: The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer (clinicaltrials.gov) - Dec 4, 2011
P2, N=90, Recruiting, Sponsor: Asan Medical Center
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., flutamide / Generic mfg.
Trial completion: Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer (clinicaltrials.gov) - Nov 20, 2011
P3, N=2028, Completed, Sponsor: Radiation Therapy Oncology Group
N=132 --> 0 Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 17, 2011
P1, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=18 --> 22
- ||||||| Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company
Trial completion: PEARLII: PGL4001 Versus GnRH-agonist in Uterine Myomas (clinicaltrials.gov) - Nov 9, 2011
P3, N=301, Completed, Sponsor: PregLem SA
N=18 --> 22 Active, not recruiting --> Completed
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: Efficacy and Safety of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 20, 2011
P2, N=487, Completed, Sponsor: Takeda
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P2 trial: A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis (clinicaltrials.gov) - Oct 13, 2011
P2, N=450, Recruiting, Sponsor: Takeda
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: DUALTRIGGER: Study of Dual Trigger Ovulation in Oocyte Donors (clinicaltrials.gov) - Sep 27, 2011
P4, N=180, Recruiting, Sponsor: Weill Medical College of Cornell University
- MVT-602 / Sumitomo Pharma
Trial termination: Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448 (clinicaltrials.gov) - Aug 25, 2011
P1/2, N=9, Terminated, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Terminated; Developing new formulation of study drug. New study to open next year under a new protocol.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer (clinicaltrials.gov) - Aug 10, 2011
P3, N=160, Active, not recruiting, Sponsor: GP-Pharm